Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Melrilimab (GSK3772847) in Healthy Participants
NCT04366349Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of melrilimab in asthma (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Area Under the Plasma Concentration Time Curve From 0 to t (AUC[0-t]) of GSK3772847 and 4 more. Started Jul 2020; status: completed.
02
Drugs
melrilimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04366349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366349.